Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
ALVERINE CITRATE
Blackrock Pharmaceuticals Limited
A03AX; A03AX08
ALVERINE CITRATE
120 milligram(s)
Capsule, hard
Product subject to prescription which may be renewed (B)
Other drugs for functional gastrointestinal disorders; alverine
Authorised
2016-03-11
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, please ask your doctor or pharmacist. - This medicine is prescribed for you only. Do not pass it on to others. It may harm them even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. - This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Alverine Citrate Capsules are and what it is used for 2. What you need to know before you take Alverine Citrate Capsules 3. How to take Alverine Citrate Capsules 4. Possible side effects 5. How to store Alverine Citrate Capsules 6. Contents of the pack and other information The name of your medicine is Alverine Citrate Capsules. The capsules contain a medicine called alverine citrate. Alverine Citrate Capsules belong to a group of medicines called anti-spasmodics. It relaxes the muscles in the intestine (gut) and uterus (womb). This helps stop the pain you feel when the muscles become tense. It is used to help people aged 12 and above who have Irritable Bowel Syndrome (IBS). Some of the symptoms of IBS are: • Abdominal pains like cramp, which come and go • Diarrhoea • Constipation • Feeling full and bloated • Wanting to go to the toilet urgently. Sometimes these symptoms are worse if you are worried or under stress. Alverine Citrate Capsules can also be used for a condition of the large intestine called painful diverticular disease of the colon, and to relieve period pains. DO NOT TAKE ALVERINE CITRATE CAPSULES IF: • you are ALLERGIC (HYPERSENSITIVE) to alverine citrate or any other ingredient in this medicine (see section 6) • your doctor has told you that you have OBSTRUCTION OF THE GUT or that your SMALL BOWEL IS NOT WORKING PROPERLY • you are pregnant and/or breast- feeding. You should not take Alverine Citrate Capsules if an Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Alverine citrate 120mg capsules, hard 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains alverine citrate equivalent to 120mg alverine citrate. Excipients with known effect: Carmoisine (E122): 0.0420 mg/Capsule. Tartrazine (E102): 0.0180 mg/Capsule. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Hard capsules. Gelatin capsule shell size #1, with blue cap (marked as ALV) and white body (marked as 120), filled with white to off- white granular powder. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Alverine citrate is indicated for the relief of smooth muscle spasm, in conditions such as irritable bowel syndrome, painful diverticular disease of the colon and primary dysmenorrhoea. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Method of administration For oral administration. Capsules should be swallowed whole. Posology Recommended dose and dosage schedules: ADULTS (INCLUDING THE ELDERLY): 1 capsule one to three times daily. CHILDREN BELOW THE AGE OF 12 YEARS: not recommended. 4.3 CONTRAINDICATIONS Paralytic ileus, intestinal obstruction, hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Additional warnings to be included in the Patient Information Leaflet: If this is the first time you have had these symptoms, consult your doctor before using any treatment. If any of the following apply do not use Alverine Citrate 120 mg; it may not be the right treatment for you. See your H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ Read the complete document